Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongrui Wang

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Cell Metabolism|January 3, 2024
Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylationXiaohui Si, Mi Shao, Xinyi Teng, et al.
Cell Reports. Medicine|January 10, 2025
CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cellsLinqin Wang, Yiyun Wang, Xiangjun He, et al.
JAMA Oncology|April 17, 2025
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical TrialMingming Zhang, Shan Fu, Jingjing Feng, et al.
Signal Transduction and Targeted Therapy|October 22, 2024
MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunBXiujian Wang, Xiao Tao, Pengjie Chen, et al.
Cell Research|September 23, 2022
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical studyYongxian Hu, Yali Zhou, Mingming Zhang, et al.
The New England Journal of Medicine|April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD ProphylaxisYongxian Hu, Mingming Zhang, Tingting Yang, et al.
Nature Medicine|March 7, 2024
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trialChristine E Brown, Jonathan C Hibbard, Darya Alizadeh, et al.
Nature Cancer|June 10, 2026
Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacyDelin Kong, Tingting Yang, Mengyu Zhao, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Cell Metabolism|January 3, 2024
Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylationXiaohui Si, Mi Shao, Xinyi Teng, et al.
Cell Reports. Medicine|January 10, 2025
CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cellsLinqin Wang, Yiyun Wang, Xiangjun He, et al.
JAMA Oncology|April 17, 2025
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical TrialMingming Zhang, Shan Fu, Jingjing Feng, et al.
Signal Transduction and Targeted Therapy|October 22, 2024
MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunBXiujian Wang, Xiao Tao, Pengjie Chen, et al.
Cell Research|September 23, 2022
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical studyYongxian Hu, Yali Zhou, Mingming Zhang, et al.
The New England Journal of Medicine|April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD ProphylaxisYongxian Hu, Mingming Zhang, Tingting Yang, et al.
Nature Medicine|March 7, 2024
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trialChristine E Brown, Jonathan C Hibbard, Darya Alizadeh, et al.
Nature Cancer|June 10, 2026
Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacyDelin Kong, Tingting Yang, Mengyu Zhao, et al.
Pageof 9